Skip to main content
Jianmin Pharmaceutical Group Co., Ltd. logo

Jianmin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 600976 ISIN · CNE000001HB7 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,559 across all filing types
Latest filing 2023-08-15 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 600976

About Jianmin Pharmaceutical Group Co., Ltd.

https://www.whjm.com/

Jianmin Pharmaceutical Group Co., Ltd. is a specialized pharmaceutical enterprise with a heritage dating back to 1637. The company focuses on the research, development, and manufacturing of Traditional Chinese Medicine (TCM) and modern healthcare products. Its core portfolio emphasizes pediatric health, gynecological treatments, and chronic disease management. Key products include Longmu Zhuanggu Granules, recognized for supporting bone development and overall health in children. The group integrates traditional pharmacological wisdom with contemporary biotechnology and standardized production processes. Jianmin Group operates through a comprehensive value chain encompassing raw material sourcing, advanced manufacturing, and a distribution network. By leveraging its status as a time-honored brand, the company maintains a strong market position in the pediatric TCM segment while expanding its presence in general wellness and prescription drug markets.

Recent filings

Filing Released Lang Actions
健民集团2023年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a '2023 年半年度报告摘要' which translates to '2023 Half-Year Report Summary'. It contains detailed financial data for the half-year period, including total assets, net profit, revenue, and other financial indicators. It also includes management discussion and analysis of business operations, marketing, R&D, production, and new business development. The document explicitly states it is a half-year report summary derived from the full half-year report. The length is over 5,000 characters and contains substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-15 Chinese
健民集团关于召开2023年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2023 half-year performance explanation meeting (业绩说明会) to be held on August 16, 2023. It includes information on the meeting time, location, participants, and how investors can participate and ask questions. The document states that the company will release its 2023 half-year report on the same day, but this document itself is not the report or the financial data. It is a notice about the upcoming investor presentation and Q&A session related to the half-year results. The document length is short (1521 characters) and it does not contain actual financial statements or substantive financial data. Therefore, it is best classified as an Investor Presentation (IP) announcement or related material rather than the Interim/Quarterly Report (IR) itself. Given the detailed description of the investor meeting and interaction, the classification as Investor Presentation (IP) is most appropriate with high confidence.
2023-08-08 Chinese
健民集团关于受让股权暨关联交易的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a related party transaction involving the acquisition of shares in an Australian listed company. It details the transaction background, approval by the board, and completion of the share transfer. The document is short (1058 characters) and serves as a progress update on a capital transaction rather than a full financial report or detailed management discussion. It does not contain financial statements or earnings data. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2023-07-25 Chinese
健民集团关于获得《药物临床试验批准通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company about receiving an official clinical trial approval notice from the national drug regulatory authority. It details the drug's basic information, development status, market context, and regulatory steps ahead. The document is relatively short (1635 characters) and serves as an announcement of a regulatory event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or audit information. It is not a report of voting results, nor a call transcript or capital update. The content fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about clinical trial approval, which does not fit other specific categories.
2023-07-25 Chinese
健民集团2023年第一次临时股东大会会议决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2023 first extraordinary general meeting of shareholders of 健民药业集团股份有限公司. It details the meeting date, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. There is no financial data or report content, only the official voting results and meeting details. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2023-07-19 Chinese
湖北德伟君尚律师事务所关于健民集团2023年第一次临时股东大会的法律意见书
Regulatory Filings
2023-07-19 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.